by Lorena Infante Lara, Vanderbilt University
The chart on the left shows the panel of peanut-reacting antibodies that the Smith lab isolated from food-allergic patients, indicating that most of the antibodies bound two peanut proteins, Ara h 2 and Ara h 6. The chart in the middle shows a subset of those antibodies separated into six color-coded categories of antibodies that all bind to specific sites within Ara h 2 and Ara h 6. The structures on the right show Ara h 6 with the binding sites identified in the second chart color coded onto its structure. Images adapted from Smith et al., Journal of Allergy and Clinical Immunology, Jan. 11, 2025, and Smith et al., Journal of Allergy and Clinical Immunology, Jan. 12, 2025, and shared in accordance with a CC BY 4.0 license. Credit: Vanderbilt University
Food-related allergies and their effects are insidiously common in the United States: over 7% of children and over 10% of adults are affected. Although a quarter of people with food allergies have an epinephrine pen, they are expensive and have to be replaced about once a year due to short expiration dates. About 40% of people with food allergies have at least one life-threatening, food allergy–related emergency department visit in their lifetimes.
But exactly what is the leading food allergy–related cause of death in the U.S. and the United Kingdom? Peanut and tree nut allergies.
Despite its prevalence, the molecular details of how peanut allergies are induced and expressed in the body are not clear. A recent pair of papers from the Vanderbilt University labs of Benjamin Spiller, associate professor of pharmacology, and Scott Smith, associate professor of medicine, dig into how peanut allergies are provoked and providing support for the use of a potential treatment option: hypoallergens. Both papers were published in the Journal of Allergy and Clinical Immunology.
IgE antibodies, which are responsible for allergies, are also the least abundant antibody type in the bloodstream and have been difficult to study. To tackle this problem, Smith and colleagues created hybrid cell lines that reliably secreted IgE antibodies against peanuts. This allowed them to test the antibodies’ structural, immunological, and functional properties and how they interact with peanut allergens.
Thanks to a comprehensive analysis, the first paper, “Antigenic determinants underlying IgE-mediated anaphylaxis to peanut,” shows that the antibodies bind most commonly to five regions within two peanut proteins. Collaborator Stokes Peebles, Elizabeth and John Murray Professor of Medicine, verified these results in an animal model, revealing which combination of antibodies binding at which protein regions can cause a life-threatening allergic reaction. Additional testing in patients with a peanut allergy validated which specific regions result in the worst allergic reactions.
“Diagnostic tests that capture the fine detail of the antibodies responsible for disease in a given patient will be essential … to identify instances where other peanut allergens are important for disease” and to guide an individual’s treatment as new therapeutic strategies emerge, the researchers said.
In their second paper, “Structural determinants of peanut induced anaphylaxis,” the Vanderbilt biomedical researchers visualized, in vast detail, the physical interfaces between the antibodies and their allergens.
“Now knowing how the antibodies interacted with the antigens, we generated antibody variants that disturbed that interaction and found that the impaired binding did not lead to anaphylaxis,” Spiller said. “These results validate ‘hypoallergens’ as a potential therapeutic against peanut allergy, which we hope to use as vaccines in sensitive individuals.”
A hypoallergen treatment would expose a person to modified peanut proteins that elicit lesser immune reactions. This treatment would reduce the strength of the allergic reaction, making the desensitization process easier.
Until we can stem the tide of food allergy incidence, our best bet is to treat it, and hypoallergens are a promising tactic. Basic molecular and structural research on the inner workings of allergy, such as the one presented here, will help to inform clinicians’ and scientists’ efforts to understand and treat food allergies.
More information: Scott A. Smith et al, Antigenic determinants underlying IgE-mediated anaphylaxis to peanut, Journal of Allergy and Clinical Immunology (2025). DOI: 10.1016/j.jaci.2024.12.1094
Scott A. Smith et al, Structural determinants of peanut-induced anaphylaxis, Journal of Allergy and Clinical Immunology (2025). DOI: 10.1016/j.jaci.2024.12.1095
Journal information:Journal of Allergy and Clinical Immunology
Provided by Vanderbilt University
Explore further
Taking vitamin E during pregnancy may decrease peanut allergy in children
Leave a Reply